**Name of Journal: *World Journal of Clinical Oncology***

**Manuscript NO:** **37236**

**Manuscript Type:** **Original Article**

***Case Control Study***

**Does low volume high-intensity interval training elicit superior benefits to continuous low to moderate-intensity training in cancer survivors?**

Toohey K *et al*. Low-volume high-intensity training in cancer survivors

**Kellie** **Toohey, Kate Pumpa, Andrew McKune, Julie Cooke, Katrina D DuBose, Desmond Yip, Paul Craft, Stuart Semple**

**Kellie Toohey, Kate Pumpa, Andrew McKune, Julie Cooke, Stuart Semple,** Discipline of Sport and Exercise Science, Faculty of Health, University of Canberra, Canberra 2605, Australia

**Kellie Toohey, Kate Pumpa, Andrew McKune, Julie Cooke, Stuart Semple,** Research Institute for Sport and Exercise, University of Canberra, Canberra 2605, Australia

**Kellie Toohey, Stuart Semple,**Health Research Institute, University of Canberra, Canberra 2605, Australia

**Andrew McKune,** Discipline of Biokinetics, Exercise and Leisure Sciences, School of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa

 **Katrina D DuBose,** the College of Health and Human Performance, East Carolina University, Greenville, NC 27858, United States

**Desmond Yip, Paul Craft,** ANU Medical School, the Australian National University, Canberra 2605, Australia

**ORCID number:** Kellie Toohey ([0000-0002-1776-6200](http://orcid.org/0000-0002-1776-6200)); Kate Pumpa ([0000-0003-3757-3972](http://orcid.org/0000-0003-3757-3972)); Andrew McKune ([0000-0002-5479-1544](http://orcid.org/0000-0002-5479-1544)); Julie Cooke ([0000-0002-4348-0118](http://orcid.org/0000-0002-4348-0118)); Katrina D DuBose ([0000-0001-9686-8741](http://orcid.org/0000-0001-9686-8741)); Desmond Yip ([0000-0002-2806-2401](http://orcid.org/0000-0002-2806-2401)); Paul Craft [0000-0002-7809-4655](http://orcid.org/0000-0002-7809-4655)); Stuart Semple (0000-0002-6143-297X ).

**Author contributions:** Toohey K performed all experiments; Semple S, Pumpa K, Cooke J, McKune A, Dubose KD, Yip D and Craft P provided vital reagents and analytical tools and were also involved in editing the manuscript; Toohey K co-ordinated and provided the collection of all the human material, Toohey K and Semple S designed the study and wrote the manuscript.

**Institutional review board statement:** National Statement on Ethical Conduct in Human Research (National Health and Medical Research Council, 2007), Human research Ethics Committee, No. 13-153.

**Informed consent statement: T**his approval is only granted if the project meets the ethical guidelines of the National Health and Medical Research Council. Individual forms which the patients signed are not able to be provided as this is against privacy laws and ethical agreements.

**Conflict-of-interest statement:** No potential conflicts of interest relevant to this article were reported.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Kellie Toohey**, **BSc, MA, Assistant Professor,** Discipline of Sport and Exercise Science, Faculty of Health, University of Canberra, University Drive, Canberra 2605, Australia. kellie.toohey@canberra.edu.au

**Telephone:** +61-02-62068873

**Received:** November 23, 2017

**Peer-review started:** November 23, 2017

**First decision:** December 27, 2017

**Revised:** December 31, 2017

**Accepted:** January 23, 2018

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To determine the impact of low volume high-intensity interval training (LVHIIT) and continuous low to moderate-intensity exercise training (CLMIT) on cardiovascular disease (CVD) risk and health outcomes in cancer survivors.

***METHODS***

Sedentary cancer survivors (*n* = 75, aged 51 ± 12 year) within 24 months of diagnosis, were randomised into three groups for 12 wk of LVHIIT (*n* = 25), CLMIT (*n* = 25) or control group (*n* = 25). The exercise intervention involved 36 sessions (three sessions per week). The LVHIIT group performed 7 x 30 s intervals (≥ 85% predicted maximal heart rate) with a 60 s rest between intervals, and the CLMIT group performed continuous aerobic training for 20 min (≤ 55% predicted maximal heart rate) on a stationary bike. Outcome variables were measured at baseline and at 12 weeks and analysed using a 3 x 2 (group x time) repeated measures ANCOVA to evaluate main and interaction effects.

***RESULTS***

Significant improvements (time) were observed for seven of the 22 variables (ES 0.35-0.97, *P* ≤ 0.05). There was an interaction effect (*P* < 0.01) after 12 wk in the LVHIIT group for six-minute walk test (*P* < 0.01; *d* = 0.97; 95%CI: 0.36, 1.56; large), sit to stand test (*P* < 0.01; *d* = -0.83; 95%CI: -1.40, -0.22; large ) and waist circumference reduction (*P* = 0.01; *d* = -0.48; 95%CI: -1.10, 0.10; medium). An interaction effect (*P* < 0.01) was also observed for quality of life in both the LVHIIT (*d* = 1.11; 95%CI: 0.50, 1.72; large) and CLMIT (*d* = 0.57; 95%CI: -0.00, 1.20; moderate) compared with the control group (*d* = -0.15; 95%CI: -0.95, 0.65; trivial).

***CONCLUSION***

Low-volume high-intensity training shows promise as an effective exercise prescription within the cancer population, showing greater improvements in cardio-respiratory fitness, lower body strength and waist circumference compared with traditional CLMIT and control groups. Both LVHIIT and CLMIT improved quality of life. A proposed benefit of LVHIIT is the short duration (3 min) of exercise required, which may entice more cancer survivors to participate in exercise, improving health outcomes and lowing the risk of CVD.

**Key words:** High-intensity exercise; Health; Oncology; Exercise prescription

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Low-volume high-intensity training is not commonly used in the rehabilitation of Cancer Survivors. In this study it shows promise as an effective exercise prescription, with greater improvements in cardio-respiratory fitness, lower body strength and waist circumference compared with traditional continuous low to moderate-intensity exercise training (CLMIT) and control groups. Low volume high-intensity interval training (LVHIIT) and CLMIT improved quality of life. A proposed benefit of LVHIIT is the short duration (3 min) of exercise required, which may entice more cancer survivors to participate in exercise, improving health outcomes and lowing the risk of cardiovascular disease.

Toohey K, Pumpa K, McKune A, Cooke J, DuBose KD, Yip D, Craft P, Semple S. Does low volume high-intensity interval training elicit superior benefits to continuous low to moderate-intensity training in cancer survivors? *World J Clin Oncol* 2018; In press

**INTRODUCTION**

Worldwide there is an increase in cancer survival rates[1]. This potentially raises the risk of cancer recurrence and other non-communicable diseases (NCDs) such as type II diabetes and cardiovascular disease (CVD)[2]. These increased health risks may be due to the effects of cancer treatments and reductions in healthy lifestyle habits, such as physical activity (PA)[3,4]. Physical activity decreases NCD risk in apparently healthy people[5], though it is not conclusive if the same trends are evident in individuals with cancer. Exercise during and after cancer treatment has been shown to be safe, improve fitness levels, and quality of life (QoL)[6,7]. Because of this, there is significant interest in the clinical use of exercise as an adjunctive therapy for improving cancer-related health outcomes.

Evidence is rapidly increasing regarding the benefits of exercise concurrent to treatment in the remediation of adverse clinical outcomes for cancer survivors[8]. It is uncommon for cancer survivors to be advised by clinicians to participate in an exercise program, despite the existence of exercise guidelines[9,10]. This may be due to the generic nature of the guidelines, limited practitioner expertise or the costs associated with some programs[11,12]. The present exercise guidelines lack detail on the type, mode, duration and intensity of exercise necessary to achieve the best outcomes for cancer survivors. Additional research is required to fill the gaps in our current knowledge to further improve exercise recommendations, the evidence-based knowledge and exercise education for cancer survivors and their treating practitioners.

Low volume high-intensity interval training (LVHIIT) is the use of small doses of high-intensity exercise to elicit physiological responses such as improved VO2 max and positive metabolic changes in skeletal muscle. The physiological changes could potentially be much higher or different to those currently being obtained with participation in other doses of activity, such as continuours, moderate-intensity exercise[13]. LVHIIT has been shown to improve VO2 peak and insulin sensitivity in apparently healthy individuals in as little as four weeks[14,15]. There is limited research examining the effects of LVHIIT in improving health outcomes for cancer survivors. Its application as a modality for use with other chronic disease populations is evolving[14,16,17], potentially due to its ability to elicit positive physiological improvements in a short period. The current study aimed to investigate and compare the effects of LVHIIT and the more commonly prescribed continuous low to moderate-intensity training (CLMIT) on improving health outcomes and reducing cardiovascular disease (CVD) risk in cancer survivors.

**MATERIALS AND METHODS**

***Participants***

Eighty-five cancer survivors (83 female and 2 male, 51.48 ± 12.45 years) were recruited for the 12-wk study. Recruitment was conducted between September 2014 and June 2016 *via* email, pamphlet distribution, word of mouth and online social media. Referrals were obtained from the medical community and community organisations. The inclusion criteria included: (1) Particpants within the first 24 months of diagnosis; (2) in the post-treatment phase of the “physical activity across the cancer experience” (PEACE) organisational model, once the acute effects of medical treatments had dissipated[18], and (3) sedentary, as described by the American College of Sports Medicine[19]. Participants were excluded if they had: (1) Brain or metastatic bone cancers; (2) bone pain; (3) resting blood pressure > 180/110 mmHg; (4) were pregnant; (5) undergoing psychotherapy treatment; (6) had musculoskeletal injuries or disabilities restricting their ability to participate in exercise.

***Randomisation***

Of the 85 participants, seven participants did not meet the inclusion criteria, and three decided not to participate due to the timing of exercise sessions. The 75 remaining participants were randomly assigned *via* an online randomisation tool into either LVHIIT (*n* = 25) or CLMIT (*n* = 25) or control (*n* = 25) group (Figure 1). A person independent of the research team used the research randomizer computer software[20] to allocate participant codes into the three groups (LVHIIT, CLMIT, and control).

Of the 75 participants, 57 completed the study (76%). In the LVHIIT group (*n* = 24), one participant changed employment and could not complete the intervention. In the CLMIT group (*n* = 21), one participant did not return after baseline assessment, one moved interstate, one was not motivated to continue, and one failed to provide a reason. In the control group (*n* = 12) one participant sustained an injury (unrelated to the project), two did not return after baseline assessment, one moved interstate, one traveled overseas, four failed to respond to the final evaluation and four did not provide a reason (Figure 1).

***Quality of life***

The Functional Assessment of Cancer Therapy-General (FACT–G) questionnaire (version 4) was used to measure quality of life (QoL) and functional capacity[21]. The FACT-G is a validated survey containing 27 items. The questions are in four categories: (1) physical well-being; (2) social/family well-being; (3) emotional well-being; and (4) functional well-being. The questionnaire is regularly used to measure QoL in cancer survivors[22] and was completed at baseline and then after the 12-week intervention.

***Anthropometrics***

The Dual X-Ray Absorptiometry (DXA) scan (GE Healthcare, Sydney, NSW, Australia) was used to measure total body composition, including; lean mass, body weight and body fat percentage[23]. The DXA scanner was calibrated each day, using a phantom spine. The manufacturers’ guidelines were followed to carry out daily quality control checks. All scans were carried out by trained densitometrists. Participants were asked to fast overnight and wear no jewellery, while being scanned. Hip and waist circumferences were measured using a standard anthropometric tape measure[24,25]. The same individual measured the circumferences at baseline and post-intervention using WHO STEPwise approach measurement protocols[25,26].

***Cardiovascular functioning***

Pulse wave velocity (PWV) and pulse wave analysis (PWA) were measured using the SphygmoCor XCEL system (SphygmoCoR; At-Cor Medical Pty Ltd., Sydney, Australia). Carotid-femoral PWV is the recognised gold standard measure of aortic stiffness, a strong independent predictor of cardiovascular risk[27,28]. PWA, which included measures of resting heart rate (RHR), augmentation index (AIx), central systolic blood pressure (CSP), central diastolic blood pressure (CDP), central pulse pressure (CPP), augmentation pressure (AP), mean arterial pressure (MAP), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were assessed at baseline and upon completion of the intervention. The pulse pressure (PP) waveform of the left carotid artery was measured with an applanation tonometer.  Participants rested supine for 10 minutes before the measurements were obtained. Twenty continuous waveforms were essential for results to be considered valid and these were used to acquire the PP waveform of the aorta, and PWV was used as a marker of aortic stiffness[29].

***Biomarkers***

Participants fasted overnight in preparation for blood sample analysis. Samples were analysed by an independent laboratory for high-sensitive C-reactive protein (CRP), insulin, glucose, and full blood count. The analysis was conducted offsite at Capital Pathology, Canberra, Australia.

***Functional capacity***

Lower body strength was measured using a repeated chair rise test (STS). The participants sat in a chair and were asked to stand and then sit as fast as possible five times, without the use of their arms[30,31]. The six-minute walk test (6MWT) was used to delineate participants’ cardiorespiratory fitness levels. Participants were asked to walk as quickly as possible for six minutes and the distance traveled was recorded[32]. The 6MWT is used extensively to assess cardiorespiratory fitness in cancer survivors[33,34].

***Intervention***

An Accredited Exercise Physiologist (AEP) supervised all exercise sessions performed over the 12-wk intervention period (three sessions per week). Participants were asked to refrain from consuming food and caffeine and participating in any exercise for two hours before baseline and post-intervention assessments. Assessments were carried out within seven days before commencement and within seven days following completion of the program[29]. The exercise sessions were carried out on a stationary bike. The LVHIIT group performed interval training (≥ 85% maximal heart rate), which consisted of a five-minute warm up, seven by 30 s intervals, with one-minute rest in between each interval, followed by a five-minute cool down (adapted from Gibala, 2012). A gradual increase in exercise was carried out by the LVHIIT group. Individuals started the first session with three intervals, with one interval added per week over the following four weeks and by the 5th week participants performed all seven intervals[29]. The CLMIT group performed continuous aerobic training (≤ 55% predicted maximal heart rate) for 20 minutes also with a five-minute warm up and cool down[29]. Age-predicted maximal heart rate was used to calculate relative intensity and the two exercise protocols were matched for appropriate energy expenditure using the calculation reported by Rognmo *et al*[36], (2004).  For each participant, their heart rate (HR) and rate of perceived exertion (RPE) were logged every minute for the CLMIT sessions. The peak HR and RPE in each interval and the resting HR and RPE between each interval were recorded during the LVHIIT sessions. Blood pressure (BP) was monitored immediately before and after each exercise session.

***Statistical analysis***

Means and standard deviations were calculated for dependent variables. An ANOVA was performed to determine if pre-intervention differences existed between the three groups. A Bonferroni post-hoc multiple comparison test was conducted to determine where group differences existed. A 3 x 2 (group x time) repeated measures ANCOVA[29] was used to evaluate main and intervention effects and was adjusted by baseline values. Effect sizes (ES) were calculated, and Cohen’s *d* values were interpreted as follows: large ≥ 0.8, medium ≥ 0.5, small ≥ 0.2 and trivial < 0.2[37]. The alpha level was set at *P* < 0.05, and SAS 9.3 (Cary, NC, United States) was used for all analyses.

**RESULTS**

***Participant characteristics***

Participant cancer diagnosis included 47 (82%) breast cancer, two (3%) ovarian cancer and one diagnosis of appendix, anal, cervical, liver, oesophageal, melanoma, leiomyosarcoma and unknown primary (15%).

The age of the participants was 51.48 ± 12.45 years, with a BMI of 26.43 ± 4.08 kg/m2 (Table 1). Baseline values for all variables were similar across the three groups except for white blood cell count, which was higher in the LVHIIT group compared with both the CLMIT group and control groups (*P* < 0.02).

For the LVHIIT group, the average HR during the 36 sessions was 147 ± 11 beats per minute (bpm), while RPE was 6 ± 3 using the Borg 1-10 scale[38,39]. The average HR and RPE at the end of each 60s recovery was 117 ± 8 bpm and RPE of 3 ± 2. The average HR for the CLMIT group was 98 ± 6 bpm and RPE was 3 ± 2 during the sessions. Overall mean session compliance was 92% (72%-100%). Ten participants attended all 36 sessions, and one participant missed ten sessions over the intervention period (data were included). There were no adverse events reported in the study.

***Fitness, functional and body composition measures***

There was a significant interaction effect (*P* < 0.01) for 6MWT. Distance walked was significantly longer for the LVHIIT group (*d* = 0.97; 95%CI = 0.36, 1.56; large) when compared with the CLMIT (*d* = 0.17; CI: -0.23, 0.99; trivial) and control (*d* = -0.13; 95%CI: -0.93, 0.67; trivial) groups (Figure 2A). There was a significant interaction effect (*P* < 0.01) for the STS test with a faster performance in the LVHIIT group (*d* = -0.83; 95%CI: -1.40, -0.22; large) compared with the CLMIT (*d* = -0.59; 95%CI: -1.20, 0.42; unclear) and control (*d* = 0.36; CI: -0.44, 1.17; unclear) groups (Figure 2B). There was a significant interaction (*P* = 0.01) effect for waist circumference; post results were significantly lower for LVHIIT (*d* = -0.48; 95%CI: -1.10, 0.10; medium) compared with CLMIT (*d* = -0.05; 95%CI: -0.66, 0.55; trivial) and control group (*d* = 0.11; 95%CI: -0.69, 0.91; trivial).

***Quality of life***

**Overall:** There was an interaction effect for overall QoL (*P* < 0.01). The QoL score was significantly improved in the LVHIIT group (*d* = 1.11; 95%CI: 0.50, 1.72; large) compared with the CLMIT group (*d* = 0.57; 95%CI: -0.00, 1.20; moderate) and the control group (*d* = -0.15; 95%CI: -0.95, 0.65; trivial) (Figure 3).

**Well-being:** An interaction effect was observed for physical well-being (*P* = 0.02). Improvements were seen in the LVHIIT (*d* = 0.89; 95%CI: 0.30, 1.48; large) and CLMIT (*d* = 0.61; 95%CI: -0.001, 1.23; medium) compared with the control group (*d* = -0.30; 95%CI: -1.09, 0.51; unclear) (Figure 3A). There was an interaction effect observed for functional well-being (*P* = 0.02). The LVHIIT group significantly improved (*d* = 0.96; 95%CI: 0.37, 1.56; large) compared to the CLMIT group (*d* = 0.64; 95%CI = 0.02, 1.26; medium) and the control group (*d* = -0.02; 95%CI: -0.82, 0.78; trivial) (Figure 3B). An interaction effect was also found for emotional well-being (*P* < 0.01). Improvements were observed for the LVHIIT group (*d* = 1.04, 95%CI: 0.43, 1.64; large) compared with the CLMIT group (*d* = 0.15; 95%CI: -0.45, 0.76; trivial) and the control group (*d* = -0.11; 95%CI: -0.92, 0.69; trivial) (Figure 3C). No interaction effect was observed for social well-being (*P* = 0.057) (Figure 3D). Changes were observed in the LVHIIT (*d* = 0.35; 95%CI: -0.22, 0.92; medium) compared to the CLMIT group (*d* = 0.20; 95%CI: -0.40, 0.80; unclear) and the control group (*d* = -0.05; 95%CI = -0.85, 0.75; trivial).

***Cardiovascular function and biomarkers***

There were no interaction effects for vessel stiffness parameters or biomarkers. However, time effects were found for markers of cardiovascular functioning. CSP (*P* = 0.07) in the LVHIIT group (*d* = -0.51; 95%CI: -1.07 - 0.10, moderate) which reduced by 4.94%. PP in the LVHIIT group decreased by 7.96% (*d* = 0.50; 95%CI: -1.05 – 0.10, moderate). AP (*P* = 0.02) in the LVHIIT group (*d* = -0.35; 95%CI: -0.91 – 0.23, small) reduced by 27%. A 22% decrease was observed in the CLMIT group (*d* = -0.34; 95% CI = -0.94 – 0.28, small) (Table 2).

**DISCUSSION**

The aim of this study was to determine the impact of LVHIIT and CLMIT on CVD risk and health outcomes in cancer survivors. There were significant improvements in functional capacity, specifically cardiorespiratory fitness, lower-limb strength, and waist circumference in participants who completed the LVHIIT compared with the CLMIT and control groups. QoL improved in both the LVHIIT group and the CLMIT group when compared with the control group, however a greater effect was observed in the LVHIIT group.

Maintaining or improving functional capacity and lower limb strength in cancer survivors is essential as it enhances survivors’ ability to move and carry out physical activities during and after treatment[40]. It also provides the functional strength to start and adhere to an exercise program which increases levels of activity[41,42]. Building lean mass through exercise builds a healthy metabolic profile, which is imperative as it assists in improving risk factors in those who have spent an increased volume of time sedentary during and following, intensive cancer treatment[43]. Participants in the LVHIIT group gained a larger effect in the sit to stand test compared with the other groups indicating improvements in lower limb strength. Possible mechanisms involved in this change could have been: (1) The increased power-output and the energy system/muscle fibre types recruited during the LVHIIT, similar to those recruited in the STS test; (2) an increased activation of the type IIa and type IIx fibres; and (3) an enhanced level of activation of the ATP/PC and glycolysis systems. An increased level of neuromuscular coordination is required at a higher-intensity of exercise, which also could have contributed to the improved strength and performance in the STS test seen in the LVHIIT group. Improvements were observed in the STS test in the LVHIIT group (20%), and in the CLMIT group (9.5%), highlighting greater increases in lower leg strength and functional capacity for those who completed the LVHIIT program. This finding was identified in our pilot study, however, due to small numbers, it was non- significant[29].

Significant improvements in cardiorespiratory fitness levels were identified through the increased distance covered in the 6MWT, with a larger effect observed in the LVHIIT group. These findings were also detected in the authors pilot study[29] and reported in other randomised controlled trials in cancer survivors[7,29,44]. The greater improvements seen in the LVHIIT group suggests that more comprehensive cardiovascular adaptations may occur with the use of high-intensity exercise. Potential mechanisms involved in increases in cardiorespiratory fitness could be due to the increased level of mitochondrial enzymes recruited in high-intensity exercise[45], which contributes to enhanced aerobic capacity of the skeletal muscles commonly seen after participating in high-intensity training. The positive impacts can contribute to changes in VO2 difference, thereby increasing maximal aerobic capacity. Improvements in cardiorespiratory fitness using high-intensity interval training has been extensively reported in healthy people, but less in the cancer survivor population[46]. LVHIIT could decrease the risk of developing additional chronic diseases such as CVD and diabetes[47] and increase cancer survival rates[48,49] faster than the commonly prescribed moderate-intensity exercise. It has been shown that cancer survivors have decreased levels of cardiorespiratory fitness levels in comparison with healthy people[50].

A cancer diagnosis has a significant impact on behaviours which in turn can negatively affect QoL[51]. QoL reductions can have a profound effect on the recovery of cancer survivors, reducing the probability of being able to move freely and maintain physical activity levels[52]. A novel and clinically relevant finding of the present study was that QoL improvements were seen in both the LVHIIT and the CLMIT group, with a greater increase observed in the LVHIIT group. To date, very few studies have investigated how different exercise protocols or intensities impact QoL[44]. While current exercise recommendations for cancer survivors prescribe low to moderate intensity exercise, evidence is accumulating that there may be greater improvements in QoL when participating in more vigorous exercise[11]. In most cases QoL changes are monitored from cancer diagnosis, to inform clinical decisions to improve patient outcomes. Linking exercise in with this conversation may assist clinicians in improving healthy behaviours to improve QoL[53].

White blood cell count was significantly reduced from baseline to post-exercise intervention in the exercise groups, with the most pronounced reduction seen in the LVHIIT group, with a small effect found. Lung cancer participants who participated in a program using resistance band exercise over 12 weeks in conjunction with chemotherapy treatment showed similar results[54] Normal WBC levels in cancer survivors are important because high levels of WBC’s are associated with chronic inflammation, autonomic nervous system imbalances and may contribute to reductions in insulin sensitivity[55]. Similarly, low WBC counts compromises an already compromised patient. Potentially both these factors would contribute to fatigue, obesity and increased risk for CVD[56,57]. To date, little work has been carried out to determine the mechanism involved in the changes in WBC’s in cancer survivors after different exercise programs[57]. Insulin levels decreased in the LVHIIT group with a small effect and increased in the CLMIT group by 13.74% with an unclear effect. These results were not significant, yet they are potentially clinically relevant findings[58]. Even a small decrease in insulin is essential in this population because of its reported role in the growth of cells, including the potential growth of tumour cells[58-60].

In the current study, a moderate effect was found in the LVHIIT group for CSP and PP with unclear effects in the CLMIT and control groups. The importance of these changes relates to the negative impact of chemotherapy drugs on the cardiovascular system. Chemotherapy drugs have been found to have a long-lasting anti-angiogenic effect on the cardiovascular system[61]. Specifically, chemotherapy has been shown to negatively impact vessel stiffness and CDP during the treatment period, with increases in BP remaining long after the treatment period[61]. Anthracyclines, cyclophosphamide and tyrosine kinase inhibitors have all been shown to increase oxidative stress[62,63]. Increases in oxidative stress can cause an overproduction of cytokines which damage the vessel wall causing endothelial dysfunction[64-66]. Endothelial dysfunction can also be caused by radiotherapy; with the adverse effects potentially having a lifelong impact on cancer survivors[65,67]. Little is known about the impact of exercise on endothelial dysfunction in cancer survivors. The current study suggests that exercise-induced cardiovascular improvements may be one mechanism whereby exercise diminishes the adverse effects that chemotherapy has on the cardiovascular system.

Limitations of this investigation were that diet; and daily physical activity levels were not controlled for in the time periods between study sessions. Although 6MWT has been shown to be a valid and reliable measure of fitness in cancer survivors, a more robust cardiorespiratory fitness test such as VO2max testing could be used. There were no male participants in this study, and as such the data should be interpreted accordingly. Participants were prescribed different ongoing medications and treatment protocols, all of which could have impacted the results; this does however represent a real world group of cancer survivors.

In conclusion, this study shows promise for the use of LVHIIT in the cancer population. The encouraging results opens up the possibility of introducing LVHIIT in therapy programs, as a shorter and more efficacious exercise to increase the fitness levels in cancer survivors. The LVHIIT protocol improved fitness and functional capacity and decreased waist circumference compared with CLMIT. Both LVHIIT and CLMIT improved QoL. LVHIIT may be an effective alternative to traditional exercise prescription within this population. The benefit of LVHIIT is that for selected variables it produces more pronounced results compared with CMIT and it is short in duration which could entice more cancer survivors to participate in exercise as time is a barrier[68]. This study highlights that the most commonly prescribed CLMIT may not be enough to induce clinically relevant changes in cancer survivors. Additional research is required to fully understand the mechanisms involved in the changes identified in this study in relation to different doses of exercise. This research would be highly beneficial to assist clinicians in the optimisation of clinical exercise recommendations for cancer survivors.

**ARTICLE HIGHLIGHTS**

***Research background***

Research into the optimum exercise guidelines for cancer survivors are not conclusive. Little evidence exists for the use of low-volume high-intensity interval training (LVHIIT) within the cancer population, even though it shows promise in other chronic populations. LVHIIT has been used in populations such as stroke, diabetes, cardiovascular disease (CVD), cardiac rehabilitation showing more pronounced health benefits than the more commonly prescribed continuous low-moderate intensity training (CLMIT). Therefore, it should be further investigated for use with cancer survivors as it is a time efficient exercise modality, with greater health benefits.

***Research motivation***

Using LVHIIT in the cancer population shows promise as a more efficient exercise prescription. The encouraging results of this study has opens the possibility of introducing LVHIIT into rehabilitation programs. LVHIIT is a time efficient exercise modality, which could be used to increase the fitness levels in cancer survivors. The LVHIIT protocol in this study improved fitness and functional capacity and decreased waist circumference compared with CLMIT and the control group. Both LVHIIT and CLMIT improved QoL. LVHIIT may be an effective alternative to traditional exercise prescription within this population. The benefit of LVHIIT is that for selected variables it produces more pronounced results compared with CMIT and it is short, which could entice more cancer survivors to participate in exercise as time is a barrier.

***Research objectives***

To determine the effectiveness of LVHIIT compared to CLMIT and a control group and to determine if LVHIIT and CLMIT improved CVD risk and health outcomes in cancer survivors. The significance of these objectives is that this form of exercise can be used to achieve more pronounced improvements in health outcomes than the commonly prescribed CLMIT.

***Research methods***

The experiments and data analysis used in this study were a mix of validated methods used before within this population (6MWT, STS, DXA, hip/waist circumference) and unique protocols which have been used with other populations, but not commonly with cancer survivors (Sphygmocor). The use of the ANCOVA analysis and effect size analysis was chosen due to the robustness that this analysis provides for the data collected.

***Research results***

There were significant improvements in functional capacity, specifically cardiorespiratory fitness, lower-limb strength, and waist circumference in participants who completed the LVHIIT compared with the CLMIT and control groups. QoL improved in both the LVHIIT group and the CLMIT group when compared with the control group, however a greater effect was observed in the LVHIIT group. Additional research is required to fully understand the mechanisms involved in the changes identified in this study in relation to different doses of exercise. This research would be highly beneficial to assist clinicians in the optimisation of clinical exercise recommendations for cancer survivors.

***Research conclusions***

Present exercise guidelines for cancer survivors lack detail on the type, mode, duration and intensity of exercise necessary to achieve best outcomes. This current research was required to fill the gaps in current knowledge to further improve exercise recommendations. LVHIIT is the use of small doses of high-intensity exercise to elicit physiological responses such as improved VO2 max and positive metabolic changes in skeletal muscle which seem greater than the commonly prescribed CLMIT. The LVHIIT physiological changes show potential for use in clinical practice in the rehabilitation of cancer survivors. At present there is limited research examining the effects of LVHIIT in improving health outcomes for cancer survivors. This study shows promise for the use of LVHIIT in the cancer population. The encouraging results opens up the possibility of introducing LVHIIT in therapy programs, as a shorter and more efficacious exercise to increase the fitness levels in cancer survivors. The benefit of LVHIIT is that for selected variables it produces more pronounced results compared with CMIT and it is short in duration which could entice more cancer survivors to participate in exercise. This study highlights that the most commonly prescribed CLMIT may not be enough to induce clinically relevant changes in cancer survivors.

***Research perspectives***

The use of VO2 max testing would be beneficial if it can be tolerated well by cancer survivors post treatment. Future research should analyse ways to measure the mechanisms involved in the changes seen in the study results and clarify how and why these changes occur.

**ACKNOWLEDGMENTS**

The authors would like to thank all the wonderful participants who gave up their time to participate in this project; this research is not possible without the support of volunteers. Thank you to the staff at the Faculty of Health Clinics for their support and use of the gym facility.

**REFERENCES**

1 **Allemani C,** Weir HK, Carreira H, Harewood R, Spika D, Wang X-S, Bannon F, Ahn JV, Johnson CJ, Bonaventure A. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). *The Lancet* 2015; **385**: 977-1010 [PMID: 25467588 DOI: 10.1016/S0140-6736(14)62038-9]

2 **Gallagher EJ**, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. *Physiol Rev* 2015; **95**: 727-748 [PMID: 26084689 DOI: 10.1152/physrev.00030.2014]

3 **Toohey K,** Pumpa K, Cooke J, Semple S. Do Activity Patterns And Body Weight Change After A Cancer Diagnosis? A Retrospective Cohort Study. *IJHSR* 2016; **6**: 110-117

4 **Holmes MD**, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. *JAMA* 2005; **293**: 2479-2486 [PMID: 15914748 DOI: 10.1001/jama.293.20.2479]

5 **Mazzeo RS**, Cavanagh P, Evans WJ, Fiatarone M, Hagberg J, McAuley E, Startzell J. Exercise and physical activity for older adults. Medicine and science in sports and exercise 1998; **30**: 992-1008

6 **Mishra SI**. Are Exercise Programs Effective for Improving Health-Related Quality of Life Among Cancer Survivors? A Systematic Review and Meta-Analysis. *Oncol Nurs Forum* 2014; **41**: E326-E42 [PMID: 25355029 DOI: 10.1188/14.ONF.E326-E342]

7 **Jones LW**, Liang Y, Pituskin EN, Battaglini CL, Scott JM, Hornsby WE, Haykowsky M. Effect of exercise training on peak oxygen consumption in patients with cancer: a meta-analysis. *Oncologist* 2011; **16**: 112-120 [PMID: 21212429 DOI: 10.1634/theoncologist.2010-0197]

8 **Lakoski SG**, Willis BL, Barlow CE, Leonard D, Gao A, Radford NB, Farrell SW, Douglas PS, Berry JD, DeFina LF, Jones LW. Midlife Cardiorespiratory Fitness, Incident Cancer, and Survival After Cancer in Men: The Cooper Center Longitudinal Study. *JAMA Oncol* 2015; **1**: 231-237 [PMID: 26181028 DOI: 10.1001/jamaoncol.2015.0226]

9 **Schmitz KH,** Courneya KS, Matthews C, Demark-Wahnefried W, Galvão DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL; American College of Sports Medicine. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. *Med Sci Sports Exerc* 2010; **42**:1409-1426 [PMID: 20559064 DOI: 10.1249/MSS.0b013e3181e0c112]

10 **Velthuis MJ**, Agasi-Idenburg SC, Aufdemkampe G, Wittink HM. The effect of physical exercise on cancer-related fatigue during cancer treatment: a meta-analysis of randomised controlled trials. *Clin Oncol* (R Coll Radiol) 2010; **22**: 208-221 [PMID: 20110159 DOI: 10.1016/j.clon.2009.12.005]

11 **Hayes SC**, Spence RR, Galvão DA, Newton RU. Australian Association for Exercise and Sport Science position stand: optimising cancer outcomes through exercise. *J Sci Med Sport* 2009; **12**: 428-434 [PMID: 19428291 DOI: 10.1016/j.jsams.2009.03.002]

12 **Donnelly JE**, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK; American College of Sports Medicine. American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. *Med Sci Sports Exerc* 2009; **41**: 459-471 [PMID: 19127177 DOI: 10.1249/MSS.0b013e3181949333]

13 **Gibala MJ**, Little JP, Macdonald MJ, Hawley JA. Physiological adaptations to low-volume, high-intensity interval training in health and disease. *J Physiol* 2012; **590**: 1077-1084 [PMID: 22289907 DOI: 10.1113/jphysiol.2011.224725]

14 **Weston KS**, Wisløff U, Coombes JS. High-intensity interval training in patients with lifestyle-induced cardiometabolic disease: a systematic review and meta-analysis. *Br J Sports Med* 2014; **48**: 1227-1234 [PMID: 24144531 DOI: 10.1136/bjsports-2013-092576]

15 **Boutcher SH**. High-intensity intermittent exercise and fat loss. *J Obes* 2011; **2011**: 868305 [PMID: 21113312 DOI: 10.1155/2011/868305]

16 **Aamot IL**, Forbord SH, Gustad K, Løckra V, Stensen A, Berg AT, Dalen H, Karlsen T, Støylen A. Home-based versus hospital-based high-intensity interval training in cardiac rehabilitation: a randomized study. *Eur J Prev Cardiol* 2014; **21**: 1070-1078 [PMID: 23613224 DOI: 10.1177/2047487313488299]

17 **Ulbrich AZ,** Angarten VG, Netto AS, Sties SW, Bündchen DC, de Mara LS, Cornelissen VA, de Carvalho T. Comparative effects of high intensity interval training versus moderate intensity continuous training on quality of life in patients with heart failure: study protocol for a randomized controlled trial. *Clinical Trials and Regulatory Science in Cardiology* 2016; **13**: 21-28 [DOI: 10.1016/j.ctrsc.2015.11.005]

18 **Courneya KS,** Friedenreich CM. Framework PEACE: an organizational model for examining physical exercise across the cancer experience. *Annals of Behavioral Medicine* 2001; **23**: 263-272 [DOI: 10.1207/S15324796ABM2304\_5]

19 **American College of Sports M**. ACSM's guidelines for exercise testing and prescription: Lippincott Williams & Wilkins; 2013

20 **Urbaniak G,** Plous S. Research Randomizer (Version 4.0)[Computer software]. Retrieved on June 22, 2013

21 **Esper P,** Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. *Urology* 1997; **50**: 920-928 [DOI: 10.1016/S0090-4295(97)00459-7]

22 **Overcash J**, Extermann M, Parr J, Perry J, Balducci L. Validity and reliability of the FACT-G scale for use in the older person with cancer. *Am J Clin Oncol* 2001; **24**: 591-596 [PMID: 11801761 DOI: 10.1097/00000421-200112000-00013]

23 **Bergman RN**, Stefanovski D, Buchanan TA, Sumner AE, Reynolds JC, Sebring NG, Xiang AH, Watanabe RM. A better index of body adiposity. *Obesity* (Silver Spring) 2011; **19**: 1083-1089 [PMID: 21372804 DOI: 10.1038/oby.2011.38]

24 **Dobbelsteyn CJ**, Joffres MR, MacLean DR, Flowerdew G. A comparative evaluation of waist circumference, waist-to-hip ratio and body mass index as indicators of cardiovascular risk factors. The Canadian Heart Health Surveys. *Int J Obes Relat Metab Disord* 2001; **25**: 652-661 [PMID: 11360147 DOI: 10.1038/sj.ijo.0801582]

25 **Organization WH.** Waist circumference and waist-hip ratio: Report of a WHO expert consultation, Geneva, 8-11 December 2008. 2011

26 **Organization WH**. WHO STEPS surveillance manual: the WHO STEP wise approach to chronic disease risk factor surveillance. 2005

27 **McDonnell BJ**, Maki-Petaja KM, Munnery M, Yasmin, Wilkinson IB, Cockcroft JR, McEniery CM. Habitual exercise and blood pressure: age dependency and underlying mechanisms. *Am J Hypertens* 2013; **26**: 334-341 [PMID: 23382483 DOI: 10.1093/ajh/hps055]

28 **Sharman JE**, Lim R, Qasem AM, Coombes JS, Burgess MI, Franco J, Garrahy P, Wilkinson IB, Marwick TH. Validation of a generalized transfer function to noninvasively derive central blood pressure during exercise. *Hypertension* 2006; **47**: 1203-1208 [PMID: 16651459 DOI: 10.1161/01.HYP.0000223013.60612.72]

29 **Toohey K**, Pumpa KL, Arnolda L, Cooke J, Yip D, Craft PS, Semple S. A pilot study examining the effects of low-volume high-intensity interval training and continuous low to moderate intensity training on quality of life, functional capacity and cardiovascular risk factors in cancer survivors. *Peer J* 2016; **4**: e2613 [PMID: 27781180 DOI: 10.7717/peerj.2613]

30 **Simmonds MJ.** Physical function in patients with cancer: psychometric characteristics and clinical usefulness of a physical performance test battery. *J pain and symptom management* 2002; **24**: 404-414 [DOI: 10.1016/S0885-3924(02)00502-X]

31 **Bohannon RW**. Test-retest reliability of the five-repetition sit-to-stand test: a systematic review of the literature involving adults. *J Strength Cond Res* 2011; **25**: 3205-3207 [PMID: 21904240 DOI: 10.1519/JSC.0b013e318234e59f]

32 **Cote CG**, Casanova C, Marín JM, Lopez MV, Pinto-Plata V, de Oca MM, Dordelly LJ, Nekach H, Celli BR. Validation and comparison of reference equations for the 6-min walk distance test. *Eur Respir J* 2008; **31**: 571-578 [PMID: 17989117 DOI: 10.1183/09031936.00104507]

33 **Enright PL**. The six-minute walk test. *Respir Care* 2003; **48**: 783-785 [PMID: 12890299]

34 **Schmidt K**, Vogt L, Thiel C, Jäger E, Banzer W. Validity of the six-minute walk test in cancer patients. *Int J Sports Med* 2013; **34**: 631-636 [PMID: 23444095 DOI: 10.1055/s-0032-1323746]

35 **Gillen JB**, Gibala MJ. Is high-intensity interval training a time-efficient exercise strategy to improve health and fitness? *Appl Physiol Nutr Metab* 2014; **39**: 409-412 [PMID: 24552392 DOI: 10.1139/apnm-2013-0187]

36 **Rognmo Ø**, Hetland E, Helgerud J, Hoff J, Slørdahl SA. High intensity aerobic interval exercise is superior to moderate intensity exercise for increasing aerobic capacity in patients with coronary artery disease. *Eur J Cardiovasc Prev Rehabil* 2004; **11**: 216-222 [PMID: 15179103 DOI: 10.1097/01.hjr.0000131677.96762.0c]

37 **Cohen J.** Statistical Power Analysis for the Behavioral Sciences (2nd ed) Hillsdale, NJ: Erlbaum; 1998

38 **Borg G**. Psychophysical scaling with applications in physical work and the perception of exertion. *Scand J Work Environ Health* 1990; **16** Suppl 1: 55-58 [PMID: 2345867 DOI: 10.5271/sjweh.1815]

39 **Borg G,** Linderholm H. Perceived exertion and pulse rate during graded exercise in various age groups. *J Internal Medicine* 1967; **181**: 194-206 [DOI: 10.1111/j.0954-6820.1967.tb12626.x]

40 **Galvão DA**, Newton RU. Review of exercise intervention studies in cancer patients. *J Clin Oncol* 2005; **23**: 899-909 [PMID: 15681536 DOI: 10.1200/JCO.2005.06.085]

41 **Mock V**, Pickett M, Ropka ME, Muscari Lin E, Stewart KJ, Rhodes VA, McDaniel R, Grimm PM, Krumm S, McCorkle R. Fatigue and quality of life outcomes of exercise during cancer treatment. *Cancer Pract* 2001; **9**: 119-127 [PMID: 11879296 DOI: 10.1046/j.1523-5394.2001.009003119.x]

42 **Irwin ML**, Crumley D, McTiernan A, Bernstein L, Baumgartner R, Gilliland FD, Kriska A, Ballard-Barbash R. Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. *Cancer* 2003; **97**: 1746-1757 [PMID: 12655532 DOI: 10.1002/cncr.11227]

43 **Vardar-Yagli N**, Sener G, Saglam M, Calik-Kutukcu E, Arikan H, Inal-Ince D, Savci S, Altundag K, Kutluk T, Ozisik Y, Kaya EB. Associations among physical activity, comorbidity, functional capacity, peripheral muscle strength and depression in breast cancer survivors. *Asian Pac J Cancer Prev* 2015; **16**: 585-589 [PMID: 25684491 DOI: 10.7314/APJCP.2015.16.2.585]

44 **Kampshoff CS**, Chinapaw MJ, Brug J, Twisk JW, Schep G, Nijziel MR, van Mechelen W, Buffart LM. Randomized controlled trial of the effects of high intensity and low-to-moderate intensity exercise on physical fitness and fatigue in cancer survivors: results of the Resistance and Endurance exercise After ChemoTherapy (REACT) study. *BMC Med* 2015; **13**: 275 [PMID: 26515383 DOI: 10.1186/s12916-015-0513-2]

45 **Gibala MJ**, Little JP, van Essen M, Wilkin GP, Burgomaster KA, Safdar A, Raha S, Tarnopolsky MA. Short-term sprint interval versus traditional endurance training: similar initial adaptations in human skeletal muscle and exercise performance. *J Physiol* 2006; **575**: 901-911 [PMID: 16825308 DOI: 10.1113/jphysiol.2006.112094]

46 **Weston M**, Taylor KL, Batterham AM, Hopkins WG. Effects of low-volume high-intensity interval training (HIT) on fitness in adults: a meta-analysis of controlled and non-controlled trials. *Sports Med* 2014; **44**: 1005-1017 [PMID: 24743927 DOI: 10.1007/s40279-014-0180-z]

47 **Leon AS**, Connett J, Jacobs DR Jr, Rauramaa R. Leisure-time physical activity levels and risk of coronary heart disease and death. The Multiple Risk Factor Intervention Trial. *JAMA* 1987; **258**: 2388-2395 [PMID: 3669210 DOI: 10.1001/jama.1987.03400170074026]

48 **Laukkanen JA**, Lakka TA, Rauramaa R, Kuhanen R, Venäläinen JM, Salonen R, Salonen JT. Cardiovascular fitness as a predictor of mortality in men. *Arch Intern Med* 2001; **161**: 825-831 [PMID: 11268224 DOI: 10.1001/archinte.161.6.825]

49 **Schmid D,** Leitzmann M. Cardiorespiratory fitness as predictor of cancer mortality: a systematic review and meta-analysis. *Ann Oncol* 2015; **26**: 272-178 [PMID: 25009011 DOI: 10.1093/annonc/mdu250]

50 **Schneider CM**, Repka CP, Brown JM, Lalonde TL, Dallow KT, Barlow CE, Hayward R. Demonstration of the need for cardiovascular and pulmonary normative data for cancer survivors. *Int J Sports Med* 2014; **35**: 1134-1137 [PMID: 24995960 DOI: 10.1055/s-0034-1375691]

51 **Zabora J,** BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. *Psychooncology* 2001; **10**: 19-28 [PMID: 11180574]

52 **Courneya KS,** Friedenreich CM. Physical exercise and quality of life following cancer diagnosis: a literature review. *Ann Behav Med* 1999; **21**: 171-179 [PMID: 10499138]

53 **Montazeri A**. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. *J Exp Clin Cancer Res* 2008; **27**: 32 [PMID: 18759983 DOI: 10.1186/1756-9966-27-32]

54 **Karvinen KH**, Esposito D, Raedeke TD, Vick J, Walker PR. Effect of an exercise training intervention with resistance bands on blood cell counts during chemotherapy for lung cancer: a pilot randomized controlled trial. *Springerplus* 2014; **3**: 15 [PMID: 24683529 DOI: 10.1186/2193-1801-3-15]

55 **Vozarova B**, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. *Diabetes* 2002; **51**: 455-461 [PMID: 11812755 DOI: 10.2337/diabetes.51.2.455]

56 **Saligan LN**, Olson K, Filler K, Larkin D, Cramp F, Yennurajalingam S, Escalante CP, del Giglio A, Kober KM, Kamath J, Palesh O, Mustian K; Multinational Association of Supportive Care in Cancer Fatigue Study Group-Biomarker Working Group. The biology of cancer-related fatigue: a review of the literature. *Support Care Cancer* 2015; **23**: 2461-2478 [PMID: 25975676 DOI: 10.1007/s00520-015-2763-0]

57 **LaVoy EC**, Fagundes CP, Dantzer R. Exercise, inflammation, and fatigue in cancer survivors. *Exerc Immunol Rev* 2016; **22**: 82-93 [PMID: 26853557]

58 **Wieser V**, Moschen AR, Tilg H. Inflammation, cytokines and insulin resistance: a clinical perspective. *Arch Immunol Ther Exp* (Warsz) 2013; **61**: 119-125 [PMID: 23307037 DOI: 10.1007/s00005-012-0210-1]

59**Giovannucci E**. Insulin and colon cancer. *Cancer Causes & Control* 1995; **6**: 164-179 [DOI: 10.1007/BF00052777]

60 **Renehan AG,** Zwahlen M, Minder C, T O'Dwyer S, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. *The Lancet* 2004; **363**: 1346-1353 [DOI: 10.1016/S0140-6736(04)16044-3]

61 **Moreo A**, Vallerio P, Ricotta R, Stucchi M, Pozzi M, Musca F, Meani P, Maloberti A, Facchetti R, Di Bella S, Giganti MO, Sartore-Bianchi A, Siena S, Mancia G, Giannattasio C. Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System. *Am J Hypertens* 2016; **29**: 158-162 [PMID: 26031304]

62 **Gorrini C**, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. *Nat Rev Drug Discov* 2013; **12**: 931-947 [PMID: 24287781 DOI: 10.1038/nrd4002]

63 **Reuter S**, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? *Free Radic Biol Med* 2010; **49**: 1603-1616 [PMID: 20840865 DOI: 10.1016/j.freeradbiomed.2010.09.006]

64 **Mozos I**, Borzak G, Caraba A, Mihaescu R. Arterial stiffness in hematologic malignancies. *Onco Targets Ther* 2017; **10**: 1381-1388 [PMID: 28424554 DOI: 10.2147/OTT.S126852]

65 **Vallerio P**, Sarno L, Stucchi M, Musca F, Casadei F, Maloberti A, Lestuzzi C, Mancia G, Moreo A, Palazzi M, Giannattasio C. Long-Term Effects of Radiotherapy on Arterial Stiffness in Breast Cancer Women. *Am J Cardiol* 2016; **118**: 771-776 [PMID: 27392510 DOI: 10.1016/j.amjcard.2016.06.001]

66 **Truskey GA,** Fernandez CE. Tissue-engineered blood vessels as promising tools for testing drug toxicity. Taylor & Francis; 2015

67 **Lenihan DJ**, Cardinale DM. Late cardiac effects of cancer treatment. *J Clin Oncol* 2012; **30**: 3657-3664 [PMID: 23008297 DOI: 10.1200/JCO.2012.45.2938]

68 **Rogers LQ**, Courneya KS, Verhulst S, Markwell S, Lanzotti V, Shah P. Exercise barrier and task self-efficacy in breast cancer patients during treatment. *Support Care Cancer* 2006; **14**: 84-90 [PMID: 16007455 DOI: 10.1007/s00520-005-0851-2]

**P-Reviewer:** Ueda H **S-Editor:** Cui LJ **L-Editor: E-Editor:**

**Specialty type:** Oncology

**Country of origin:** Australia

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Baseline characteristics of participants**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristics** | **LVHIIT*****n* = 24** | **CMIT*****n* = 21** | **Control*****n* = 12** |
| Sociodemographic |  |  |  |
| Age, mean (SD), yr | 48 (11.9) | 52 (12.4) | 57 (11.5) |
| Sex, *n* (%) male | F, 25 (0) | F, 21 (0) | F, 12 (0) |
| Comorbidity, *n* (%) yes | 2 (0.8) | 1 (0.4) | 0 (0) |
| Diagnosis, *n* (%) |  |  |  |
| Breast  | 21 (88) | 16 (75) | 10 (83) |
| Ovarian |  | 1 (5) | 1 (8.5) |
| Appendix |  | 1 (5) |  |
| Anal |  |  | 1 (8.5) |
| Cervical | 1 (4) |  |  |
| Liver | 1 (4) |  |  |
| Esophageal  | 1 (4) |  |  |
| Melanoma |  | 1 (5) |  |
| Leiomyosarcoma |  | 1 (5) |  |
| Unknown primary |  | 1 (5) |  |
| Stage of disease, *n* (%) |  |  |  |
| Stage 1-11 | 19 (79) | 16 (76) | 10 (83) |
| Stage 11 – 1V | 5 (21) | 5 (24) | 2 (17) |
| Type of treatment, *n* (%) |  |  |  |
| Surgery | 21 (88) | 20 (95) | 12 (100) |
| Radiation therapy | 18 (75) | 13 (62) | 10 (83) |
| Hormone therapy | 19 (79) | 15 (71) | 9 (75) |
| Types of chemotherapy, *n* (%) |  |  |  |
| TAC | 7 (29) | 4 (19) | 1 (8) |
| FEC | 5 (21) | 3 (14) | 3 (25) |
| TAC/FEC combinations | 2 (8) | 3 (14) | 2 (17) |
| Capecitabine and oxaliplatin |  | 1 (5) |  |
| Carboplatin and paclitaxel | 1 (4) |  | 1 (8) |
| Cisplatin | 1 (4) |  |  |
| CHOP | 1 (4) |  |  |
| ABVD | 1 (4) | 1 (5) | 1 (8) |
| Other | 2 (8) | 3 (14) |  |
| No chemotherapy | 4 (17) | 6 (29) | 4 (33) |

LVHIIT: Low volume high-intensity training; CLMIT: Continuous low to moderate-intensity training; TAC: Taxotere, adriamycin, cyclophosphamide; FEC: Fluorouracil, epirubicin, cyclophosphamide; CHOP: Cyclophosphamide, doxorubicin, vincristine, prednisone; ABVD: Doxorubicin, bleomycin, vinblastine, dacarbazine.

**Table 2 Changes in risk factors from pre-to post intervention (Mean ± SD)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **LVHIIT group** |  | **CLMIT group** |  | **Control group** |  |
|  | ***n* = 24** |  | ***n* = 21** |  | ***n* = 12** |  |
| Variable | **Pre** | **Post** | **ES (95%CI)** | **Pre** | **Post** | **ES (95%CI)** | **Pre** | **Post** | **ES (95%CI)** |
| Weight (kg) | 72.9 ± 11.7 | 72.8 ± 11.4 | -0.01 (-0.57, 0.56) | 69.4 ± 14.3 | 70.4 ± 14.9 | 0.06 (-0.54, 0.67) | 65.5 ± 13.1 | 65.9 ± 13.9 | 0.03 (-0.77, 0.83) |
| Body fat (%) | 42.2 ± 7.9 | 41.4 ± 7.8 | -0.1 (-0.67, 0.46) | 43.0 ± 6.7 | 44.4 ± 9.5 | 0.17 (-0.44, 0.78) | 37.7 ± 9.2 | 37.0 ± 10.5 | -0.07 (-0.87, 0.73) |
| Fat mass (kg) | 30.6 ± 9.1 | 29.2 ± 8.7 | -0.16 (-0.72, 0.41) | 30.5 ± 12.4 | 31.0 ± 12.1 | 0.05 (-5.6, 0.65) | 24.3 ± 9.0 | 24.4 ± 9.5 | 0.01 (-0.79, 0.81) |
| Lean mass (kg) | 40.7 ± 6.4 | 41.0 ± 7.2 | 0.05 (-0.52, 0.61) | 38.8 ± 6.2 | 39.3 ± 6.8 | 0.07 (-0.53, 0.68) | 38.8 ± 6.7 | 39.2 ± 6.9 | 0.06 (-0.74, 0.86) |
| Waist (cm)1,2 | 91.1 ± 11.7 | 85.7 ± 10.51 | -0.48 (-1.10, 0.10) | 93.1 ± 13.1 | 92.4 ± 13.3 | -0.05 (-0.66, 0.55) | 89.1 ± 9.5 | 90.3 ± 11.6 | 0.11 (-0.69, 0.91) |
| Hip (cm)1 | 108.3 ± 10.3 | 104.8 ± 10.51 | -0.37 (-0.91, 0.23) | 107.9 ± 11.3 | 107.0 ± 14.8 | -0.07 (-0.67, 0.54) | 104.1 ± 9.4 | 104.3 ± 8.9 | -0.02 (-0.82, 0.78) |
| Resting HR (bpm) | 76.3 ± 12.0 | 73.3 ± 12.4 | -0.24 (-0.81, 0.32) | 73.9 ± 11.9 | 72.3 ± 9.8 | -0.14 (-0.75, 0.46) | 74.5 ± 11.9 | 73.7 ± 12.6 | -0.07 (-0.87, 0.74) |
| SBP (mmHg) | 127.3 ± 18.3 | 121.8 ± 9.7 | -0.39 (-0.95, 0.20) | 130.9 ± 15.5 | 130.4 ± 14.7 | -0.58 (-0.64, 0.57) | 123.9 ± 15.4 | 128.1 ± 12.7 | 0.3 (-0.51, 1.10) |
| DBP (mmHg) | 79.7 ± 8.3 | 77.8 ± 6.9 | -0.25 (-0.82, 0.32) | 81.5 ± 11.7 | 81.4 ± 6.5 | -0.01 (-0.62, 0.59) | 78.2 ± 5.3 | 79.9 ± 6.1 | 0.30 (-0.51, 1.10) |
| MAP | 97.2 ± 10.8 | 93.9 ± 7.9 | -0.36 (-0.92, 0.22) | 100.7 ± 12.5 | 98.4 ± 8.9 | -0.21 (-0.82, 0.39) | 96.6 ± 6.2 | 95.9 ± 8.6 | -0.09 (-0.89, 0.71) |
| CSP (mmHg) 1 | 118.6 ± 17.7 | 111.3 ± 10.71 | -0.51 (-1.07, 0.10) | 121.8 ± 15.9 | 119.9 ± 8.9 | -0.14 (-0.75, 0.46) | 116.7 ± 12.1 | 115.3 ± 13.5 | -0.11 (-0.91, 0.69) |
| PP (mmHG) | 35.7 ± 12.8 | 30.8 ± 6.8 | -0.5 (-1.05, 0.10) | 35.7 ± 10.6 | 36.0 ± 7.5 | 0.04 (-0.57, 0.64) | 35.0 ± 11.4 | 34.1 ± 11.4 | -0.08 (-0.88, 0.72) |
| AP (mmHg)1 | 8.1 ± 8.1 | 5.9 ± 4.41 | -0.35 (-0.91, 0.23) | 9.3 ± 8.6 | 7.0 ± 4.8 | -0.34 (-0.94, 0.28) | 10.3 ± 6.6 | 8.0 ± 9.2 | -0.29 (-1.09, 0.52) |
| AIx (%) | 19.9 ± 14.7 | 18 ± 11.6 | -0.14 (-0.71, 0.42) | 22.5 ± 18.4 | 11.59 ± 18.8 | -0.24 (-1.20, 0.03) | 26.6 ± 12.5 | 10.0 ± 18.3 | -1.06 (-1.91, -0.20) |
| CDP (mmHg) | 83.25 ± 9.13 | 80.3 ± 7.9 | -0.34 (-0.92, 0.22) | 85.9 ± 10.6 | 82.8 ± 7.1 | -0.34 (-0.95, 0.27) | 82.7 ± 6.9 | 81.1 ± 7.1 | -0.22 (-1.03, 0.57) |
| PWV (m/s) | 6.6 ± 1.5 | 6.5 ± 1.2 | -0.12 (-0.64, 0.49) | 6.8 ± 1.5 | 6.9 ± 1.0 | 0.11 (-0.53, 0.68) | 6.8 ± 1.5 | 6.2 ± 1.4 | -0.41 (-1.22, 0.40) |
| STS (s)1,2 | 10.1 ± 2.8 | 8.1 ± 2.11 | -0.83 (-1.40, -0.22) | 10.6 ± 2.8 | 9.2 ± 2.0 | -0.59 (-1.20, 0.42) | 9.6 ± 2.3 | 10.49 ± 2.7 | 0.36 (-0.44, 1.17) |
| 6MWT (m)1,2 | 510.7 ± 114.9 | 607.7 ± 85.51 | 0.97 (0.36, 1.56) | 483.1 ± 72.3 | 518.6 ± 94.5 | 0.17 (-0.23, 0.99) | 494.2 ± 128.7 | 477.7 ± 127.1 | -0.13 (-0.93, 0.67) |
| Glucose (mmol/L) | 4.9 ± 0.0 | 4.8 ± 0.5 | -0.28 (-0.85, 0.29) | 5.1 ± 0.6 | 4.9 ± 0.7 | -0.31 (-0.92, 0.30) | 5.1 ± 0.4 | 4.9 ± 0.4 | -0.5 (-1.31, 0.31) |
| CRP (mg/L) | 2.9 ± 3.5 | 2.7 ± 3.2 | -0.07 (-0.63, 0.50) | 4.5 ± 5.1 | 4.7 ± 4.9 | 0.04 (-0.56 – 0.64) | 2.0 ± 1.1 | 2.0 ± 1.6 | 0 (-0.80, 0.80) |
| Insulin (mU/L) | 11.4 ± 6.8 | 9.0 ± 4.9 | -0.41 (-1.36, -0.19) | 13.1 ± 10.4 | 11.3 ± 9.3 | -0.18 (-0.79 – 0.42) | 9.9 ± 5.6 | 10.7 ± 6.3 | 0.13 (-0.67, 0.94) |
| WBC (x 109/L)1 | 6.9 ± 2.5 | 5.7 ± 2.51 | -0.46 (-1.05, 0.10) | 5.6 ± 2.0 | 5.2 ± 1.8 | -0.21 (-0.82 – 0.40) | 5.4 ± 0.7 | 4.9 ± 0.9 | -0.62 (-1.44, 0.20) |

1Time effect; 2Interaction effect. ES: Effect size; HR: Heart rate; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MAP: Mean arterial pressure; CSP: Central systolic pressure; PP: Central pulse pressure; AP: Arterial pressure; Aix: Augmentation index (stiffness); CDP: Central diastolic pressure; PWV: Pulse wave velocity; STS: Sit-to-stand test; 6MWT: 6-min walk test; CRP: C-reactive protein; WBC: White blood cell.

Assessed for eligibility (*n* = 85)

# Enrollment

Excluded (*n* = 10)

Did not meet inclusion criteria (*n* = 7)

Decided not to participate (*n* = 3)

Randomized (*n* = 75)

Allocation

Discontinued intervention (*n* = 4)

Did not return after assessment (*n* = 1)

Moved away (*n* = 1)

Unmotivated (*n* = 1)

Did not give reason (*n* = 1)

# Analysis

**Follow up**

Analysed (*n* = 24)

Discontinued intervention (*n* = 1)

Changed employment – could not fit in intervention

Discontinued intervention (*n* = 13)

Injury – unrelated to project (*n* = 1)

Did not return after assessment (*n* = 2)

Moved away (*n* = 1)

Travelled overseas – family issue (*n* = 1)

Unmotivated (*n* = 4)

Did not give reason (*n* = 4)

CONTROL Group - Allocated to intervention

(*n* = 25)

LVHIIT Group - Allocated to intervention

(*n* = 25)

CLMIT Group - Allocated to intervention

(*n* = 25)

Analysed (*n* = 12)

Analysed (*n* = 21)

**Figure 1 Consort diagram.**

AB

**Figure 2 Changes in cardiorespiratory fitness and sit to stand for** **low volume high-intensity interval training, continuous low to moderate-intensity exercise training and control groups.**

 A**B**

**C**

**D**

**Figure 3 Changes in quality of life subscales for** **low volume high-intensity interval training, continuous low to moderate-intensity exercise training, and control groups.**